Coagulation Disorders in COVID-19: Role of Toll-like Receptors

被引:31
作者
Biswas, Indranil [1 ]
Khan, Gausal A. [2 ]
机构
[1] Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA
[2] Fiji Natl Univ, Coll Med Nursing & Hlth Sci, Dept Physiol & Physiotherapy, Suva, Fiji
关键词
COVID-19; coagulation disorders; TLR3; tissue factor; TISSUE FACTOR; DENGUE VIRUS; KEY ROLE; INFECTION; ACTIVATION; THROMBOSIS;
D O I
10.2147/JIR.S271768
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Coronavirus disease 2019 (COVID-19) has spread rapidly throughout the world. The range of the disease is broad but among hospitalized patients with COVID-19 are coagulation disorders, pneumonia, respiratory failure, and acute respiratory distress syndrome (ARDS). The excess production of early response proinflammatory cytokines results in what has been described as a cytokine storm, leading to an increased risk of thrombosis, inflammations, vascular hyperpermeability, multi-organ failure, and eventually death over time. As the pandemic is spreading and the whole picture is not yet clear, we highlight the importance of coagulation disorders in COVID-19 infected subjects and summarize it. COVID-19 infection could induce coagulation disorders leading to clot formation as well as pulmonary embolism with detrimental effects in patient recovery and survival. Coagulation and inflammation are closely related. In this review, we try to establish an association between virus infections associated with innate immune activation, inflammation and coagulation activation.
引用
收藏
页码:823 / 828
页数:6
相关论文
共 53 条
[51]   Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection [J].
Wright, Franklin L. ;
Vogler, Thomas O. ;
Moore, Ernest E. ;
Moore, Hunter B. ;
Wohlauer, Max, V ;
Urban, Shane ;
Nydam, Trevor L. ;
Moore, Peter K. ;
McIntyre, Robert C., Jr. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 231 (02) :193-203
[52]  
Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI [10.1056/NEJMoa2001017, 10.1172/JCI89857]
[53]  
Zuo Y, 2020, MED PHARM